Mitsubishi Tanabe Domestic Sales Grow 7 Percent
This article was originally published in PharmAsia News
Mitsubishi Tanabe domestic sales from April to December grew 7.1 percent to ¥282.3 billion
You may also be interested in...
TOKYO - Japan's Ministry of Health, Labor and Welfare has suspended Mitsubishi Tanabe Pharma's manufacturing and sales operations for 25 days because it was determined a subsidiary of the company fabricated data for Medway Injection 5%, the world's first genetically engineered transgenic human serum albumin, MHLW officials said April 13, and regulatory authorities may level additional administrative penalties against the company
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.